Baynes Roy D.'s Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Apr 16, 2026
- Accession no.
- 0001680739-26-000005
- Filed
- Apr 16, 2026
- Trade date
- Apr 14, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 5 derivative transactions. Open-market sales total $1.35M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Baynes Roy D.CIK 0001680739 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | Common Stock | MOption exerciseAcquired | +8,000 | $17.94 | +$143,520 | 45,500 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseAcquired | +9,000 | $15.43 | +$138,870 | 54,500 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseAcquired | +4,500 | $18.27 | +$82,215 | 59,000 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseAcquired | +4,500 | $21.38 | +$96,210 | 63,500 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseAcquired | +6,750 | $17.11 | +$115,492.5 | 70,250 | Direct | |
| Apr 14, 2026 | Common Stock | SSaleDisposed | −26,000 | $41.07 | −$1,067,820 | 44,250 | Direct | |
| Apr 14, 2026 | Common Stock | SSaleDisposed | −6,750 | $42.12 | −$284,310 | 37,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 14, 2026 | Common Stock | MOption exerciseDisposed | −8,000 | $0.00 | $0 | 0 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseDisposed | −9,000 | $0.00 | $0 | 0 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseDisposed | −4,500 | $0.00 | $0 | 4,500 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseDisposed | −4,500 | $0.00 | $0 | 4,500 | Direct | |
| Apr 14, 2026 | Common Stock | MOption exerciseDisposed | −6,750 | $0.00 | $0 | 6,750 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.